Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLSTU:V9G0 27 Days Inventory is 9.16 as of Jun. 2026, which is 20% below its 10-year median of 11.42. GuruFocus rates STU:V9G0 with a GF Score™ of 27/100 and a GF Value™ of €2.45. The stock has 4 warning signs investors should review. Among 177 Medical Diagnostics & Research companies, XWELL ranks better than 94.92% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). XWELL's Average Total Inventories for the
three
months ended in Jun. 2026 was €0.37 Mil. XWELL's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €3.64 Mil.
Hence, XWELL's Days Inventory for the
three
months ended in Jun. 2026 was 9.16.
The historical rank and industry rank for XWELL's Days Inventory or its related term are showing as below:
STU:V9G0'
s Days Inventory Range Over the Past 10 Years
Min: 6.89 Med: 11.42 Max: 78.14
Current: 9.55
During the past 13 years, XWELL's highest Days Inventory was 78.14. The lowest was 6.89. And the median was 11.42.
STU:V9G0's Days Inventory is ranked better than 94.92% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.64
vs STU:V9G0: 9.55
XWELL's Days Inventory
increased
from Jun. 2025 (8.70) to Jun. 2026 (9.16).
It might indicate that XWELL's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
XWELL's Inventory Turnover for the
three
months ended in Jun. 2026 was 9.97.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
XWELL's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.06.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
XWELL's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
XWELL's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
XWELL Days Inventory Related Terms
XWELL Days Inventory Historical Data
* Premium members only.
The historical data trend for XWELL's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:V9G0 vs MBAI, NDRA, BIAF: Days Inventory Comparison
For the Diagnostics & Research subindustry, XWELL's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Days Inventory distribution charts can be found below:
* The bar in red indicates where XWELL's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XWELL (STU:V9G0) has a Days Inventory of 9.16 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on XWELL and its competitors. This is 20% below median its historical median of 11.42. Over the past decade, XWELL's Days Inventory has ranged from 6.89 to 78.14. According to the industry distribution chart, XWELL ranks #9 out of 177 companies in the Medical Diagnostics & Research industry, placing it in the top 5.1%.
Is XWELL's Days Inventory too high?
XWELL's current Days Inventory of 9.16 is 20% below median its 10-year median of 11.42. Over the past 10 years, this metric has ranged from a low of 6.89 to a high of 78.14. The Medical Diagnostics & Research industry median Days Inventory is 67.64. XWELL's value of 9.16 is 86.5% below this industry median. Based on the distribution chart, XWELL ranks #9 out of 177 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, XWELL has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does XWELL's Days Inventory compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #9 out of 177 companies for Days Inventory. This places XWELL in the top 5% of its industry — outperforming the majority of peers. The industry median Days Inventory is 67.64. XWELL's value of 9.16 is 86.5% below this benchmark. Historically, XWELL's own Days Inventory has ranged from 6.89 to 78.14 over the past decade. While the company's 10-year median is 11.42 vs. the industry median of 67.64, XWELL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 67.64, based on 177 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XWELL's current Days Inventory of 9.16 is 86.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on XWELL and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 67.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XWELL's current Days Inventory is 9.16, which is 20% below median its own 10-year median of 11.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
XWELL (STU:V9G0) has a current Days Inventory of 9.16. The stock's GF Value™ is €2.45, compared to a current price of €2.96 — trading 20.8% above its estimated fair value. The current Days Inventory is 9.16, which is 20% below median its 10-year median of 11.42 and 86.5% below the Medical Diagnostics & Research industry median of 67.64. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For XWELL (STU:V9G0), the current Days Inventory is 9.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (STU:V9G0) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of €2.96 is trading 20.8% above its estimated GF Value™ of €2.45.
Key valuation signals for STU:V9G0:
Days Inventory: 9.16 (20% below median its 10-year median of 11.42)
GF Value™: €2.45 vs. price of €2.96 (20.8% above fair value)
Industry Position: 86.5% below the Medical Diagnostics & Research median (#9 of 177)
No single metric tells the full story. See the STU:V9G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for STU:V9G0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:V9G0 has been successfully added to your 
